▲ +87.47% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Atara Biotherapeutics in the last 3 months. The average price target is $34.25, with a high forecast of $78.00 and a low forecast of $14.00. The average price target represents a 87.47% upside from the last price of $18.27.
The current consensus among 10 investment analysts is to buy stock in Atara Biotherapeutics. This Buy consensus rating has held steady for over two years.
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, and viral diseases, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell lymphomas, as well as ATA188 that are in Phase I clinical trials for the treatment of multiple sclerosis. In addition, it develops ATA2321 for acute myeloid leukemia; ATA230 for cytomegalovirus; ATA368 for HPV; ATA520 for Wilms Tumor 1; and ATA621 for BK and JCV. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was founded in 2012 and is headquartered in South San Francisco, California.